Compositions and methods for growth factor modulation

Patent metadata

Field	Value
Publication number	US-9399676-B2
Application number	US-201514795033-A
Country	US
Kind code	B2
Filing date	Jul 9, 2015
Priority date	May 6, 2013
Publication date	Jul 26, 2016
Grant date	Jul 26, 2016

Abstract

Provided herein are proteins, antibodies, assays and methods useful for modulating growth factor levels and/or activities. In some embodiments, such growth factors are members of the TGF-β superfamily of proteins.

First claim

The invention claimed is:

1. A method of producing an antibody capable of binding a growth factor prodomain complex (GPC), said GPC consisting of at least one GDF-8 growth factor and at least one GDF-8 prodomain, said method comprising:
a. expressing proGDF-8 (SEQ ID NO: 5),
b. forming the GPC by subjecting the expressed proGDF-8 (SEQ ID NO: 5) to enzymatic cleavage with one or more of furin, bone morphogenetic protein-1 (BMP-1), mammalian tolloid protein (mTLD), mammalian tolloid-like 1 (mTLL1), and mammalian tolloid-like 2 (mTLL2),
c. carrying out solid-phase or solution-phase enrichment with an antibody fragment phage display library, wherein the GPC formed by enzymatic cleavage is used as a target antigen;
d. selecting phage particles bound to the GPC formed by enzymatic cleavage; and
e. producing recombinant antibodies having complementarity determining region (CDR) amino acid sequences obtained from the antibody fragments expressed at the surface of the phage particles selected in (d).

2. The method of claim 1 , further comprising
f. conducting a negative selection binding assay of the recombinant antibodies produced in (e) to remove antibodies that bind to one or more undesired antigens.

3. The method of claim 2 , wherein said one or more undesired antigens are selected from the group consisting of GDF-8 prodomain, GDF-8 growth factor, murine proGDF-8, proGDF-11, proTGF-β1 and a protein with an amino acid sequence selected from the group consisting of SEQ ID NOs: 207-230.

4. The method of claim 1 , wherein phage particle binding is determined using one or more binding assays selected from the group consisting of enzyme-linked immunosorbent assays, surface plasmon resonance assays, and flow cytometry assays.

5. The method of claim 1 , wherein said enzymatic cleavage comprises sequential enzymatic cleavage with at least two enzymes.

6. The method of claim 1 , further comprising
f. screening the recombinant antibodies of (e) and selecting those which reduce GDF-8 growth factor activity.

7. The method of claim 6 , wherein said enzymatic cleavage comprises sequential enzymatic cleavage with at least two enzymes.

Assignees

• Scholar Rock Inc

Inventors

• Schurpf Thomas
• Mahanthappa Nagesh K
• Straub Michelle Marie

Classifications

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title